Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

NCT06713148 EARLY_PHASE1 NOT_YET_RECRUITING

This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of intratumoral Administration of IDOV-SAFETM in patients with advanced solid tumors.

Details

Lead sponsor	Fudan University
Phase	EARLY_PHASE1
Status	NOT_YET_RECRUITING
Enrolment	42
Start date	Thu Apr 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced Malignant Solid Tumor

Interventions

• IDOV-SAFETM